Skip to main content
Top
Published in: BMC Ophthalmology 1/2020

01-12-2020 | Edema | Research article

Intravitreal conbercept for branch retinal vein occlusion induced macular edema: one initial injection versus three monthly injections

Authors: X. Chen, T. M. Hu, J. Zuo, H. Wu, Z. H. Liu, Y. X. Zhan, Y. Xia, J. Wang, W. Wei

Published in: BMC Ophthalmology | Issue 1/2020

Login to get access

Abstract

Background

To compare the efficacy of one initial intravitreal injection of conbercept (IVC) versus three monthly IVCs in patients with macular edema (ME) after branch retinal vein occlusion (BRVO). Both options were followed by a pro re nata (PRN) retreatment regimen.

Methods

This study retrospectively investigated and followed 60 patients with acute ME secondary to BRVO for over a year. 30 subjects received one initial injection (1 + PRN group); while, 30 received three monthly injections (3 + PRN group). The functional and anatomic outcomes were assessed during each follow-up.

Results

The general characteristics of the 60 subjects were as follows: mean [SD] age, 57.43 [13.06] years; 33 [55%] female; 36 [60%] non-ischemic form. Both groups showed a stable gain in visual acuity (VA) with similar logMAR (mean ± SD) (1 + PRN group 0.308 ± 0.399, 3 + PRN group 0.34 ± 0.352) during the first 12 months. Additionally, both groups exhibited a significant reduction in central foveal thickness (CFT) with no statistically significant difference between them (1 + PRN group 222.1 μm ± 197.1 μm, 3 + PRN group 228.4 μm ± 200.2 μm). Both treatment groups had similar improvements in logMAR and anatomic outcomes over time. The stratified analysis showed that patients with the non-ischemic form and those with the ischemic form had similar improvements in VA (0.346 ± 0.366 VS 0.29 ± 0.39, P = 0.575) during the 12 months follow-ups. The number of injections was lower in the 1 + PRN group (4.0 ± 1.6) than in the 3 + PRN group (4.7 ± 1.3) (P = 0.068). No adverse effects or unexpected safety issues were reported in either group.

Conclusions

Conbercept yielded significant improvements in VA and CFT among patients with BRVO induced ME, independent of their retinal ischemia status. The results showed that the 3 + PRN regimen do not lead to better functional outcomes or lower treatment needs in clinical practice as compared to the 1 + PRN regimen.
Literature
2.
go back to reference Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–19. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–19.
3.
go back to reference Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041–9. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041–9.
4.
go back to reference Vance SK, Chang LK, Imamura Y, et al. Effects of intravitreal anti-vascular endothelial growth factor treatment on retinal vasculature in retinal vein occlusion as determined by ultra wide-field fluorescein angiography. Retin Cases Brief Rep. 2011;5(4):343–7..PubMed Vance SK, Chang LK, Imamura Y, et al. Effects of intravitreal anti-vascular endothelial growth factor treatment on retinal vasculature in retinal vein occlusion as determined by ultra wide-field fluorescein angiography. Retin Cases Brief Rep. 2011;5(4):343–7..PubMed
5.
go back to reference PA C. Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2012:30–5. PA C. Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2012:30–5.
6.
go back to reference Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 2012;90(2):e98–e103..PubMed Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 2012;90(2):e98–e103..PubMed
7.
go back to reference Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102–12 e1..PubMed Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102–12 e1..PubMed
8.
go back to reference Leitritz MA, Gelisken F, Ziemssen F, et al. Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol. 2013;97(2):215–9.PubMed Leitritz MA, Gelisken F, Ziemssen F, et al. Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol. 2013;97(2):215–9.PubMed
9.
go back to reference Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538–44..PubMed Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538–44..PubMed
10.
go back to reference Wecker T, Ehlken C, Bühler A, et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol. 2017;101(3):353–9.PubMed Wecker T, Ehlken C, Bühler A, et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol. 2017;101(3):353–9.PubMed
11.
go back to reference Miwa Y, Muraoka Y, Osaka R, et al. Ranibizumab for macular edema after branch retinal vein occlusion: One initial injection versus three monthly injections. Retina (Philadelphia, Pa). 2017;37(4):702–9. Miwa Y, Muraoka Y, Osaka R, et al. Ranibizumab for macular edema after branch retinal vein occlusion: One initial injection versus three monthly injections. Retina (Philadelphia, Pa). 2017;37(4):702–9.
12.
go back to reference Sun Z, Zhou H, Lin B, et al. Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion. Retina (Philadelphia, Pa.). 2017;37(9):1723–30.. Sun Z, Zhou H, Lin B, et al. Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion. Retina (Philadelphia, Pa.). 2017;37(9):1723–30..
13.
go back to reference Willoughby AS, Vuong VS, Cunefare D, et al. Choroidal Changes After Suprachoroidal Injection of Triamcinolone Acetonide in Eyes With Macular Edema Secondary to Retinal Vein Occlusion. Am J Ophthalmol. 2018;186:144–51..PubMed Willoughby AS, Vuong VS, Cunefare D, et al. Choroidal Changes After Suprachoroidal Injection of Triamcinolone Acetonide in Eyes With Macular Edema Secondary to Retinal Vein Occlusion. Am J Ophthalmol. 2018;186:144–51..PubMed
14.
go back to reference Liu K, Song Y, Xu G, et al. Conbercept for treatment of Neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol. 2019;197:156–67.PubMed Liu K, Song Y, Xu G, et al. Conbercept for treatment of Neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol. 2019;197:156–67.PubMed
15.
go back to reference Osaka R, Muraoka Y, Miwa Y, et al. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections. Ophthalmologica. 2018;239(1):27–35..PubMed Osaka R, Muraoka Y, Miwa Y, et al. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections. Ophthalmologica. 2018;239(1):27–35..PubMed
16.
go back to reference Singer M, Tan CS, Bell D, et al. Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion. Retina (Philadelphia, Pa.). 2014;34(9):1736–42.. Singer M, Tan CS, Bell D, et al. Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion. Retina (Philadelphia, Pa.). 2014;34(9):1736–42..
17.
go back to reference Tadayoni R, Waldstein SM, Boscia F, et al. Sustained benefits of Ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology. 2017;124(12):1778–87..PubMed Tadayoni R, Waldstein SM, Boscia F, et al. Sustained benefits of Ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology. 2017;124(12):1778–87..PubMed
18.
go back to reference Li F, Sun M, Guo J, et al. Comparison of Conbercept with Ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion. Curr Eye Res. 2017;42(8):1174–8.PubMed Li F, Sun M, Guo J, et al. Comparison of Conbercept with Ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion. Curr Eye Res. 2017;42(8):1174–8.PubMed
Metadata
Title
Intravitreal conbercept for branch retinal vein occlusion induced macular edema: one initial injection versus three monthly injections
Authors
X. Chen
T. M. Hu
J. Zuo
H. Wu
Z. H. Liu
Y. X. Zhan
Y. Xia
J. Wang
W. Wei
Publication date
01-12-2020
Publisher
BioMed Central
Keywords
Edema
Ranibizumab
Published in
BMC Ophthalmology / Issue 1/2020
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-020-01494-x

Other articles of this Issue 1/2020

BMC Ophthalmology 1/2020 Go to the issue